Hepatitis infection in haemodialysis patients

Nephrology

Volumn 7, Issue 3, 2002, Pages 101-109

  Huang, Chiu Ching ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Haemodialysis; Hepatitis B; Hepatitis C; Hepatitis G; TT virus

Indexed keywords

ALPHA INTERFERON; LAMIVUDINE; RIBAVIRIN;

BIOACCUMULATION; DISEASE COURSE; DRUG INDUCED DISEASE; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HUMAN; INFECTIOUS HEPATITIS; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; MORBIDITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; TORQUE TENO VIRUS; TRANSPLANTATION; VIREMIA;

EID: 0036047951     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1797.2002.00105.x     Document Type: Review

References (93)

1. The long-term outcome of hepatitis B infection in hemodialysis patients
2. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients
3. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: Clinical and biochemical appraisal
4. Hepatitis B disease in dialysis and transplant patients
5. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients
6. Liver disease and the antigen in HBsAg carriers with chronic renal failure
7. Hepatitis B surface antigenemia in a chronic hemodialysis program: Lack of influence on morbidity and mortality
8. Hepatitis B associated liver disease in dialysis patients: Role of vaccination
9. A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant
10. Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis
11. Histopathological impacts of hepatitis virus infection in hemodialysis patients: Should liver biopsy be performed before renal transplantation?
12. The impact of renal transplantation on the course of hepatitis B liver disease
13. Long-term patient and renal allograft survival in HBsAg infection: A recent update
14. Renal transplant recipients and chronic liver disease: Statistical evaluation of predisposing factors
15. The significance and implications of hepatitis B infection in renal transplant recipients
16. Natural history of hepatitis B virus infection in renal transplant recipients: A fifteen year follow-up
17. Chronic hepatitis in kidney allograft recipients
18. The reemergence of hepatitis B virus infection in haemodialysis centers
19. Production of interleukin-6, tumor necrosis factor and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients
20. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
21. Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis
22. Limited benefits of IFN-α therapy in renal graft candidates with chronic viral hepatitis B or C
23. Biochemical pharmacology (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents
24. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
25. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region
26. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
27. Lamivudine as initial treatment for chronic hepatitis B in the United States
28. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
29. A one year trial of lamivudine for chronic hepatitis B
30. Efficacy of lamivudine in patients with hepatitis B antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
31. Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109
32. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
33. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
34. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
35. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
36. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
37. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
38. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
39. Hepatitis C virus infection in dialysis and renal transplantation
40. Hepatitis C in dialysis patients
41. Risk of death among chronic dialysis patients infected with hepatitis C virus
42. The impact of renal transplantation on survival in hepatitis C positive end-stage renal disease patients
43. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease
44. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients
45. Incidence and risk factors of hepatitis C virus infection in a haemodialysis unit
46. Incidence of seroconversino for hepatitis C virus in chronic haemodialysis patients: A prospective study
47. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units
48. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: A prospective study
49. Universal precautions prevent hepatitis C virus transmission: A 54 month follow-up of the Belgian multi-center study
50. Hepatitis C the clinical spectrum of disease
51. Long-term mortality after transfusions-associated nonA-nonB hepatitis
52. Histological evolution of chronic hepatitis C. Factors related to progression
53. Hepatitis C and hepatocellular carcinoma
54. Clinical outcomes after transfusion associated hepatitis C
55. Hepatitis C virus-induced liver disease in dialysis patients
56. Eradication of hepatitis C virus RNA after alpha-interferon therapy
57. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen in tertiary referral centers in the United States
58. Hepatitis C virus type (II) infection in France and Italy
59. Genetic diversity of hepatitis C virus: Implications for pathogenesis, treatment, and prevention
60. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C
61. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon alpha therapy in chronic hepatitis C patients
62. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
63. Increased frequency of HLA DR13 in hepatitis C virus carries with persistently normal ALT values
64. Mutations in the non-structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
65. Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients
66. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy
67. Pharmacokinetics of αIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications
68. HCV-RNA levels are lowered during hemodialysis in patients with chronic hepatitis C
69. Pharmacokinetics of interferon alpha-2b in haemodialysis
70. The tolerance and efficacy of interferon-α in haemodialysis patients with HCV infection: A multi-centre, prospective study
71. Treatment of hepatitis C virus infection in dialysis patients
72. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: Results of a pilot study
73. Hepatitis G virus infection in a hemodialysis unit: Prevalence and clinical implications
74. Hepatitis G virus infection in hemodialysis patients
75. High prevalence of hepatitis G virus (HGV) infections in dialysis staff
76. Hepatitis G virus infection among hemodialysis patients: True infection or innocent bystander
77. High prevalence of GB virus-C infection in haemodialysis patients
78. GBV-C/HGV infection in end-stage renal disease
79. The cloning and clinical implications of HGV and HGBV-C
80. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection
81. Hepatitis G virus infection: A work in progress
82. Histopathologic impact of GB virus C infection of chronic hepatitis C
83. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology
84. Detection of a novel DNA virus (TTV) in blood donors and blood products
85. Fecal excretion of non-enveloped DNA virus (TTV) associated with posttransfusion non-A-G hepatitis
86. High prevalence of TT virus in human saliva and semen
87. Detection of TTV DNA in sera of patients with chronic liver diseases and interferon efficiency
88. Presence of TT virus in French blood donors and intravenous drug users
89. Molecular cloning and characterisation of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology
90. Detection of a novel DNA virus (TT virus) in blood donors and blood products
91. TT virus infection in French hemodialysis patients: Study of prevalence and risk factors
92. High prevalence of TT virus (TTV) infection in patients on maintenance hemodialysis: Frequent mixed infections with different genotypes and lack of evidence of associated liver disease
93. TT virus infection in hemodialysis patients